Stanos (Stanozolol)

About the Product

Stanos is a research compound from Driada Medical, containing Stanozolol. Stanozolol is a synthetic anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT). Its chemical formula is C₂₁H₃₂N₂O, with a molecular weight of 328.5 g/mol and a CAS number of 10418-03-8.

The compound is characterized by a unique structural feature—a pyrazole ring fused to the A-ring of the steroid nucleus. This modification, combined with its 5α-reduced structure and 17α-methyl group, provides two key characteristics for research purposes:

• The 17α-methyl group hinders hepatic metabolism, enabling bioavailability for oral research models.

• The 5α-reduced structure prevents aromatization to estrogen, differentiating its receptor activity from testosterone.

The product is intended for laboratory research use only and features an integrated QR code on the packaging for detailed product verification.

• Product Name: Stanos (Stanozolol)

• Brand: Driada Medical

• Form: Solution for research applications

• CAS: 10418-03-8

• For Research Use Only.

Research Applications & Mechanism of Action

• Paradoxical Androgen Receptor Agonist: Stanozolol functions as an agonist at the androgen receptor (AR). However, its mechanism presents a distinct research profile: despite having a low binding affinity for the AR (approximately 22% of DHT in some studies, or a relative binding affinity of <0.05 compared to methyltrienolone), stanozolol is a potent activator of AR-mediated transcription and signaling.

  • This paradox—low affinity but strong transcriptional activation—is a key area of research interest. Studies suggest that stanozolol may induce a distinct conformational change in the AR upon binding, which effectively promotes the recruitment of transcriptional coactivators and the displacement of corepressors.

• Anabolic Profile: Relative to testosterone (ratio 1:1), the anabolic:androgenic ratio of stanozolol in rodent models is approximately 1:1 to 1:3. It is classified as having weak AR binding, yet in transactivation assays, it functions as a potent activator.

• Serum Protein Binding: Stanozolol exhibits very low affinity for serum sex hormone-binding globulin (SHBG), resulting in a significantly higher fraction of the compound circulating in the free, unbound state (the pharmacologically active form), which influences its bioavailability.

• Gene Expression Research: The compound has been shown to regulate the expression of various genes, including the androgen receptor (AR) itself, Fas Receptor (FasR), and 5-alpha reductase 2 (SRD5A2) in certain cell models.

• Cardiovascular & Metabolic Research: Animal studies have demonstrated that stanozolol administration can lead to cardiac hypertrophy, increased mean arterial pressure, and alterations in baroreflex control of heart rate. It can also induce oxidative stress and activate inflammatory signaling pathways (e.g., NF-κB/P65) in cardiac tissue.

• Hepatotoxicity Research: Human case studies reveal a specific biochemical profile of stanozolol-induced liver injury characterized by marked elevation of bilirubin, mild rise in transaminases, and near-normal GGT.

Research & Scientific Background

• Chemical Background: Stanozolol is a 17α-alkylated anabolic steroid formed by the condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. It was historically used to treat various medical conditions, including anemia and hereditary angioedema.

• Androgen Receptor Binding & Activation Research: Several studies have characterized stanozolol's distinct pharmacology:

  • A 1984 study found its relative binding affinity to the AR was less than 0.05 compared to methyltrienolone, a reference compound.

  • Subsequent research (2005) confirmed that while stanozolol is a low-affinity ligand for the AR in vitro, it is a potent activator in cell-based transactivation assays.

  • Computational docking studies distinguish its binding energy profile from other oral steroids such as methyltestosterone and oxandrolone.

• In Vivo Studies: In rat models, stanozolol administered at doses of 5 mg/kg/week caused increases in mean arterial pressure (control: 116 ± 2 mmHg; treated: 126 ± 2.5 mmHg), cardiac output, and cardiac hypertrophy. Higher doses (20 mg/kg/week) resulted in increased total peripheral resistance.

• Human Liver Injury Research: A prospective study (2025) evaluating 18 cases of stanozolol-induced liver injury found a mean latency to symptom onset of 55 days. The cohort consisted of young males (ages 19–48) using stanozolol for aesthetic purposes. Doses reported ranged from 50 to 200 mg daily or three times weekly for up to 8 weeks.

• Genetic Variability Research: While direct studies on stanozolol pharmacogenomics are limited, the field of pharmacogenomics indicates that genetic variations in drug-metabolizing enzymes can influence compound response. Stanozolol's distinct AR activation profile and receptor binding dynamics provide a basis for investigating how genetic factors may influence individual responses in research models.